Rituxan better than Fingolimod, Dymethyl fumarate and Natalizumab
https://onlinelibrary.wiley.com/doi/ful ... acn3.51111
Interpretation
RTX demonstrated superior effectiveness and discontinuation outcomes compared to FTY and DMF. Although RTX demonstrated similar effectiveness and discontinuation compared to NTZ, RTX had superior effectiveness during months 6–24 and fewer discontinuations when excluding discontinuations due to insurance issues. Results suggest superiority of RTX in reducing disease activity and maintaining long‐term treatment in a real‐world MS cohort.
Rituxan better than Fingolimod, Dymethyl fumarate and Natalizumab
-
- Similar Topics
- Replies
- Views
- Last post